Precision Screening for Preclinical Alzheimer Disease: The Ascendance of Plasma p-tau217 as a Scalable Biomarker
This review synthesizes recent high-impact evidence on plasma p-tau217, demonstrating its superior utility in identifying amyloid pathology, predicting cognitive decline, and optimizing recruitment for primary prevention trials in cognitively unimpaired individuals.